Banook Central Imaging selected by Servier to provide innovative image analysis services based on a combination of RECIST, IrRC and TGR criteria
Banook Central Imaging (Banook CI), a global imaging core lab for drug and device clinical trials, announces today that it has been selected by Servier to assess the potential anti-tumor activity of a novel monoclonal antibody based on the RECIST 1.1 (Response Evaluation Criteria in Solid Tumors) and Immune-Related Response criteria (IrRC). Following on from the successful research conducted by Gomez-Roca et al[1] at Gustave Roussy Cancer Center, this multicenter, international phase I study in patients with breast cancer will also incorporate the use of Tumor Growth Rates (TGR). TGR assessment will allow Servier to explore the growth rate before and after treatment. This will allow for a more detailed look at the effectiveness of the drug in development than that provided by RECIST 1.1 alone.
“In this new era of personalized medicine, it may be essential to redefine the response to treatment and identify those patients in whom the treatment has a beneficial impact on tumor growth,” said Professor Jean-Charles Soria, head of the early drug development program at the Institut Gustave Roussy (IGR), in Villejuif (France). “We are convinced that the collaboration between Servier, IGR and Banook CI creates a unique opportunity to bring forward a new generation of efficacy assessment criteria in drug development.”
Throughout this trial Banook CI will leverage their comprehensive imaging core lab services, including a specialized radiologic review and analysis of all images. Employing state-of-the art software, Banook CI supports and automates all the necessary tasks for the rigorous follow-up of the radiologic exams. This allows readers to focus on accurate image interpretation and response analysis. Combining this sophisticated and robust imaging software with experienced imaging professionals allows Banook CI to incorporate innovative analyses such as TGR with RECIST and IrRC.
“We are delighted to start this new collaboration with Servier,” said Dr. Pascal Voiriot, founder and chief executive officer at Banook CI. “Our customers increasingly attempt to include new methodologies such as TGR or IrRC in their clinical programs. We are always looking for innovative solutions aimed at better and earlier evaluation of the response of patients to the new therapeutic approaches for cancer. Banook CI is setting the bar for the industry.”
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.